Athena Global Investors LLC reduced its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 29.8% during the second quarter, Holdings Channel reports. The institutional investor owned 8,725 shares of the biopharmaceutical company’s stock after selling 3,705 shares during the period. Bristol-Myers Squibb makes up 1.0% of Athena Global Investors LLC’s portfolio, making the stock its 29th largest position. Athena Global Investors LLC’s holdings in Bristol-Myers Squibb were worth $642,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. increased its position in Bristol-Myers Squibb by 1.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 44,742,184 shares of the biopharmaceutical company’s stock valued at $2,858,131,000 after buying an additional 844,233 shares during the last quarter. Jennison Associates LLC increased its position in Bristol-Myers Squibb by 4.1% in the second quarter. Jennison Associates LLC now owns 28,064,140 shares of the biopharmaceutical company’s stock valued at $2,064,118,000 after buying an additional 1,099,210 shares during the last quarter. BlackRock Group LTD increased its position in Bristol-Myers Squibb by 0.3% in the first quarter. BlackRock Group LTD now owns 15,139,964 shares of the biopharmaceutical company’s stock valued at $967,140,000 after buying an additional 38,123 shares during the last quarter. Geode Capital Management LLC increased its position in Bristol-Myers Squibb by 1.9% in the first quarter. Geode Capital Management LLC now owns 13,534,575 shares of the biopharmaceutical company’s stock valued at $862,835,000 after buying an additional 254,653 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in Bristol-Myers Squibb by 9.8% in the first quarter. TIAA CREF Investment Management LLC now owns 10,372,071 shares of the biopharmaceutical company’s stock valued at $662,568,000 after buying an additional 921,866 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.53% during trading on Friday, hitting $56.72. 6,002,454 shares of the company were exchanged. The stock’s 50-day moving average is $58.51 and its 200-day moving average is $67.50. Bristol-Myers Squibb Co. has a 12 month low of $55.02 and a 12 month high of $77.12. The company has a market capitalization of $94.77 billion, a price-to-earnings ratio of 33.17 and a beta of 0.61.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The company earned $4.90 billion during the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. Bristol-Myers Squibb’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb Co. will post $2.62 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 2.69%. The ex-dividend date is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.

BMY has been the topic of several recent research reports. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, July 6th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Wednesday, July 13th. Berenberg Bank reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 12th. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.79 price target on the stock in a research report on Tuesday, June 7th. Finally, TheStreet upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, May 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $69.64.

In other news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the transaction, the director now owns 334,499 shares of the company’s stock, valued at $19,022,958.13. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.